ArsenalBio scores $85 mln Series A

South San Francisco-based ArsenalBio, a developer of a cell therapy company, has secured $85 million in Series A financing. The investors included Westlake Village BioPartners, the Parker Institute for Cancer Immunotherapy, Kleiner Perkins, the University of California, San Francisco Foundation Investment Company, Euclidean Capital and Osage Venture Partners.

Source: Press Release